β-Thalassemias.

@article{Taher2021Thalassemias,
  title={$\beta$-Thalassemias.},
  author={Ali T. Taher and Khaled M. Musallam and Maria Domenica Cappellini},
  journal={The New England journal of medicine},
  year={2021},
  volume={384 8},
  pages={
          727-743
        }
}

Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.

There is no high-quality evidence to support or challenge the continued use of hydroxyurea for managing people with transfusion-dependent β-thalassaemia, and the efficacy and safety of this treatment are still unclear.

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm

The future outlook for disease control and prevention of morbidity and mortality when curative therapy is not or practical will fall to optimizing the use of conventional and supportive therapies, novel disease modifying agents, and/or their combination.

Amlodipine: Can act as an antioxidant in patients with transfusion-dependent β-thalassemia? A double-blind, controlled, crossover trial.

Clinically, amlodipine therapy is an efficacious adjuvant treatment with conventional iron chelators for improving the levels of MDA and TAC in patients with TDT.

Prevalence and molecular characterization of alpha and beta-Thalassemia mutations among Hakka people in southern China

The study establishes molecular features of thalassemia among Hakka people in Heyuan and finds common genotypes of α-thal and β-thal mutations were consistent with allele frequencies of mutations.

Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients

The case of a patient affected by transfusion-dependent β-thalassemia (TDT) developing acute promyelocytic leukemia (APL) is reported, and experience suggests that TDT patients suffering pre-existing comorbidities may develop a potentially fatal complication during ATRA therapy.

MALDI-TOF-MS for Rapid Screening and Typing of β-Globin Variant and β-Thalassemia through Direct Measurements of Intact Globin Chains.

MALDI-TOF-MS is a highly accurate, predictive tool that could be suitable for large-scale screening and clinical classification of β-globin disorders.

[Diagnostics and treatment of alpha- and beta-thalassemias].

  • H. Cario
  • Medicine
    Deutsche medizinische Wochenschrift
  • 2022
The complex treatment of the patients represents a medical and socioeconomic challenge with the need for structured interdisciplinary clinical care and close collaboration among healthcare providers, regulatory authorities, and health care insurance companies.
...